FDAnews Drug Daily Bulletin

Attorneys general from 31 states have joined the FTC in urging the Supreme Court to review the legality of — and halt — generic and brand-drug makers’ pay-for-delay agreements by overturning an 11th Circuit Court’s decision that upheld the legality of reverse patent settlements. The states said the court should take up the issue to resolve a lower-court split that has spurred industry uncertainty.
International Pharmaceutical Regulatory Monitor